Neurologists and neuroscience professionals this week from around the world gathered at the American Academy of Neurology (AAN) 65th Annual Meeting in San Diego. The Multiple Sclerosis Center at Swedish Neuroscience Institute was pleased to co-author a few research trials presented at the meeting:
Teriflunomide and pregnancy
Dr. Lily Jung-Henson, neurologist and Neurologist and chief of staff at Swedish Issaquah spoke on behalf of a team of researchers about teriflunomide and a report on the safety of women who became pregnant on the medication. Teriflunomide is a once-daily, oral disease-modifying therapy (DMT) recently approved in the United States to treat relapsing multiple sclerosis. Clinical trials for teriflunomide took place among the many research studies for new treatments Swedish Neuroscience Institute offers patients with multiple sclerosis.
Subset of a trial looking at endurance effects of Dalfampridine (AMPYRA®)
Dr. Angeli Mayadev, physical medicine and rehabilitation specialist at the MS Center, participated in this study of a medication to improve walking speed in people with MS. Dalfampridine -ER 10 mg twice daily significantly improved 6-minute walking distance compared to placebo. Dalfampridine 5 mg twice daily did not improve distance compared to placebo. Researchers also found that significantly more patients treated with the higher dose had at least a 20 percent improvement in walking distance.
Arbaclofen clinical trial
Dr. Mayadev also participated in a study of Arbaclofen in patients with multiple sclerosis. The poster presented at the AAN Annual Meeting gives an update on enrollment, background, objectives, methods and early data of the multi-center trial. The trial is in an extension phase and results will likely come out later in 2013.
Each of these studies is part of our MS Center’s commitment to rehabilitation efforts in MS. Visit the MS Center research page to learn more about Swedish’s multiple sclerosis studies.